clinicaltrialsarena.com
BioNTech's mRNA Cancer Immunotherapy Misses Primary Endpoint in Phase 2/3 Trial for Head and Neck Ca
BioNTech announced that its mRNA-based cancer immunotherapy, BNT113, in combination with Keytruda, did not achieve a statistically significant improvement in progression-free survival (PFS) in a Phase